A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease

Clinical trial NCT01907087 · COMPLETED

Trial details

NCT number: NCT01907087
Sponsor: BioMarin Pharmaceutical
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Jansky-Bielschowsky Disease Batten Disease Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 CLN2 Disease

Start date: 2013-09-01
Primary completion: 2015-11-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.